Myriad Genetics, Inc. (MYGN) reported a loss of 1 cent per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 11 cents. The figure improved from the year-ago quarter’s loss of 21 cents.The quarter’s adjustments exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization.RevenuesTotal revenues rose 12% year over year to $202.2 million in the quarter under review. The figure topped the Zacks Consensus Estimate by 4.6 ...